Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.

In the near future, the Minimal Residual Disease (MRD) testing industry is poised to experience remarkable growth and ...

During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD ...

Driven EcosystemsDublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease Testing Market by Product Type (Instruments, Reagents & Kits, Software & Services), Test Techniques (Flow ...

After living with lymphoma for 15 and a half years, my doctor has suggested reducing the dose of my medication and possibly ...

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal ...

Plasma-based molecular residual disease analysis shows the potential to predict disease recurrence in lung cancer patients by 4.7 months.

This tool is a type of molecular residual disease (MRD)detector, which is used after patients have completed their primary treatment in order to monitor their cancer status. Researchers say it ...

Can't beat that and it's pretty easy too!" - Martha Ray Deen Apple Tart Cheesecake (mrd) has been awarded a Blue Ribbon from The Just A Pinch Test Kitchen who prepare and review thousands of real ...